- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03219645
Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke (GDPRS)
July 13, 2017 updated by: RenJi Hospital
A Randomized, Active-Controlled,Blinded-Endpoint and Parallel Group Pilot Trial Comparing the Antiplatelet Effects of Ginkgo Diterpene Lactone Meglumine Injection Plus Aspirin Versus Aspirin Alone in Patients With Acute Ischemic Stroke
This study evaluates the addition of Ginkgo Diterpene Lactone Meglumine Injection to aspirin in the treatment of acute ischemic stroke.Half of patient will receive Ginkgo Diterpene Lactone Meglumine Injection(25mg once/day D1-D14) and aspirin(300mg loading dose,then 100mg once/day D2-D14) in combination, while the other half will receive aspirin(300mg loading dose,then 100mg once/day D2-D14).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The GDPRS trial is a prospective, randomized, single-centre, open-label, active-controlled, blinded-endpoint trial (a PROBE design concerning clinical trial).
A total of approximately 40 patients (18 years≤Age≤ 80 years) with acute ischemic stroke (NIHSS < 12), who can be treated within 72 hours of symptom onset will be enrolled.
Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content: 1) one group will receive a Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14(the injection must be added slowly into 0.9% sodium chloride injection diluted to 250 ml , intravenous drip for about 2 hours), combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14. 2) the other group will receive a 300 mg loading dose of Aspirin on the day of randomization, followed by Aspirin 100 mg once/day from Day 2 to Day 14.
The primary objective is to assess the anti-platelet effects of Ginkgo Diterpene Lactone Meglumine Injection combined with Aspirin versus Aspirin alone in patients with acute ischemic stroke.
The study consists of 4 visits including the day of randomization, 24 hours after the first anti-platelet agents,Day 14±2days and Day 90±7days.
The antiplatelet effects will be analyzed in total subjects.
The trial is anticipated to complete in 6 months from the first subject recruitment , with 40 subjects recruited.
A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study.
The trial has been approved by IRB(Institutional Review Board) /EC(Ethics Committee) in Renji hospital,Shanghai Jiaotong University School of Medicine.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of informed consent;
- Female or male with 18 years ≤age ≤ 80 years;
- Within 72 hours symptom onset of ischemic stroke (diagnosis standard by the Chinese medical association of the fourth national conference on cerebrovascular disease);
- Modified Rankin Scale Score ≤2 at the time of randomization;
- NIHSS <12 points at the time of randomization;
- Diagnosis of collaterals abstraction by phlegm and blood stasis in Traditional Chinese Medicine.
Exclusion Criteria:
- Diagnosis of infection, cancer, autoimmune diseases,severe renal or hepatic insufficiency or deep vein thrombosis,etc;
- Current treatment (last dose given within 10 days before randomization) with anticoagulation therapy or anti-platelet therapy;
- Presumed cardiac source of embolus, e.g., atrial fibrillation, known prosthetic cardiac valves, suspected endocarditis or other cardioembolic pathology for stroke;
- Low or high platelet count (<100 x10^9/L or >300 x10^9/L);
- Clear indication for anticoagulation or thrombolysis;
- Head imaging studies have confirmed that, encephalitis, brain tumor, brain abscess and cause similar symptoms of disease, or confirm with hemorrhagic cerebral infarction, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc;
- Blood pressure elevated(systolic > 220mmHg or diastolic >120mmHg);
- Pregnancy or lactation, and women of childbearing age not practicing reliable contraception who do not have a documented negative pregnancy test;
- Known allergic to acetylsalicylic acid or Ginkgo Diterpene Lactone Meglumine;
- With hemorrhagic disease or have a bleeding tendency;
- Clear indication for Dual Antiplatelet Therapy with acetylsalicylic acid and clopidogrel;
- Have to be fed through a nasal feeding tube;
- Contraindication to acetylsalicylic acid;
- Presumed probably poor adherence, or any other inappropriate conditions for patients to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Ginkgo and aspirin
Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14.
The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
|
The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
Other Names:
Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Other Names:
|
PLACEBO_COMPARATOR: aspirin
Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
|
Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ARU on day 14
Time Frame: 14 days
|
Residual Platelet Reactivity defined as the value of Aspirin Reaction Unit (ARU) measured by VerifyNow® assay on day 14.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PL-12 AA at 24 hours and day 14
Time Frame: 24 hours,14 days
|
Residual platelet reactivity detected by PL Platelet Analyser (SINNOWA®)using the inducer of acetylsalicylic acid.
|
24 hours,14 days
|
PL-12 ADP at 24 hours and day 14
Time Frame: 24 hours,14 days
|
Residual platelet reactivity detected by PL Platelet Analyser (SINNOWA®)using the inducer of adenosine diphosphate.
|
24 hours,14 days
|
PL-12 PAF at 24 hours and day 14
Time Frame: 24 hours,14 days
|
Residual platelet reactivity detected by PL Platelet Analyser (SINNOWA®)using the inducer of PAF(Platelet activating factor).
|
24 hours,14 days
|
PL-12 Coll at 24 hours and day 14
Time Frame: 24hours,14 days
|
Residual platelet reactivity detected by PL Platelet Analyser (SINNOWA®) using the inducer of collegen.
|
24hours,14 days
|
PL-12 Adr at 24 hours and day 14
Time Frame: 24 hours,14 days
|
Residual platelet reactivity detected by PL Platelet Analyser (SINNOWA®) using the inducer of adrenaline.
|
24 hours,14 days
|
TEG-AA on day 14
Time Frame: 14 days
|
Residual platelet reactivity defined as the value of Maximum Amplitude- acetylsalicylic acid (MA-AA) measured by Thrombelastography Platelet Mapping Assay (TEG) using the inducer of acetylsalicylic acid.
|
14 days
|
TEG-ADP on day 14
Time Frame: 14 days
|
Residual platelet reactivity defined as the value of Maximum Amplitude- adenosine diphosphate (MA-AA) measured by Thrombelastography Platelet Mapping Assay (TEG) using the inducer of adenosine diphosphate
|
14 days
|
ARU at 24 hours
Time Frame: 24 hours
|
Residual platelet reactivity defined as the value of Aspirin reaction unit (ARU) measured by VerifyNow® assay at 24 hours.
|
24 hours
|
AA HOPR VerifyNow®
Time Frame: 24 hours,14 days
|
High on-treatment platelet reactivity defined as Aspirin reactivity unit (ARU)> 555 measured by VerifyNow® assay.
|
24 hours,14 days
|
Aspirinworks
Time Frame: 24 hours,14days
|
Residual platelet reactivity detected by AspirinWorks.
|
24 hours,14days
|
Impairment
Time Frame: 14 days,90days
|
Changes in NIHSS and mRS at 14 days and 90 days.
|
14 days,90days
|
Modified Rankin Scale score changes
Time Frame: 14 days,90 days
|
Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6
|
14 days,90 days
|
New vascular events defined as any event of the following: Any stroke (ischemic or hemorrhage).
Time Frame: 14 days
|
All the new vascular events will be assessed by at least two neurologists based on neuroimaging and clinical feature.
When there was disagreement, a third senior neurologist was consulted to reach a consensus decision.
|
14 days
|
New composite clinical vascular events (ischemic stroke/ hemorrhagic stroke/TIA/ myocardial infarction/ vascular death) as a cluster.
Time Frame: 14days,90 days
|
The PLATO(Platelet Inhibition and Patient Outcomes) definition of fatal/life-threatening of major bleed is any one of the following: Fatal, Intracranial, Intrapericardial bleed with cardiac tamponade, Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery, Clinically overt or apparent bleeding associated with a decrease in hemoglobin(Hb) of more than50 g/L, Transfusion of 4 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding.
The PLATO definition of other of major bleed is any one of the following:Significantly disabling (eg.
intraocular with permanent vision loss), Clinically overt or apparent bleeding associated with a decrease in Hb of 30 g/L to 50 g/L, Transfusion of 2-3 units (whole blood or PRBCs) for bleeding.
|
14days,90 days
|
Major bleed (PLATO definition), including fatal/life-threatening and other.
Time Frame: 14days,90 days
|
The PLATO(Platelet Inhibition and Patient Outcomes) definition of fatal/life-threatening of major bleed is any one of the following: Fatal, Intracranial, Intrapericardial bleed with cardiac tamponade, Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery, Clinically overt or apparent bleeding associated with a decrease in hemoglobin(Hb) of more than50 g/L, Transfusion of 4 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding.
The PLATO definition of other of major bleed is any one of the following:Significantly disabling (eg.
intraocular with permanent vision loss), Clinically overt or apparent bleeding associated with a decrease in Hb of 30 g/L to 50 g/L, Transfusion of 2-3 units (whole blood or PRBCs) for bleeding.
|
14days,90 days
|
Intracranial hemorrhagic events.
Time Frame: 14days,90 days
|
Intracranial hemorrhagic events is assessed by brain computed tomography (CT) or gradient recalled echo (GRE) T2 star weighted MRI.
|
14days,90 days
|
Total mortality.
Time Frame: 14days,90 days
|
All deaths reported post-randomization will be recorded and adjudicated.
Deaths will be subclassified by the adjudication committee as cardiovascular or non-cardiovascular.
|
14days,90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
July 15, 2017
Primary Completion (ANTICIPATED)
October 31, 2017
Study Completion (ANTICIPATED)
December 31, 2017
Study Registration Dates
First Submitted
July 5, 2017
First Submitted That Met QC Criteria
July 13, 2017
First Posted (ACTUAL)
July 17, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 17, 2017
Last Update Submitted That Met QC Criteria
July 13, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Infarction
- Brain Infarction
- Stroke
- Ischemic Stroke
- Ischemia
- Cerebral Infarction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- 2016-194(3)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Ginkgo Diterpene Lactone Meglumine Injection
-
Beijing Tiantan HospitalBeijing Bionovo Medicine Development Co., Ltd.Completed
-
Dongzhimen Hospital, BeijingCompletedStroke | Nervous System Diseases | Ischemic Stroke | Brain Ischemia | Cerebral Infarction | Brain InfarctionChina
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Shanghai Yueyang Integrated Medicine HospitalRecruiting
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.CompletedIschemic StrokeChina
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completed
-
GuerbetCompleted
-
Jiangsu Kanion Pharmaceutical Co., LtdCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditionsUnited States